4.5 Article

LCZ696, an angiotensin receptor-neprilysin inhibitor, improves cardiac function with the attenuation of fibrosis in heart failure with reduced ejection fraction in streptozotocin-induced diabetic mice

相关参考文献

注意:仅列出部分参考文献,下载原文获取全部文献信息。
Article Cardiac & Cardiovascular Systems

MicroRNA signatures differentiate preserved from reduced ejection fraction heart failure

Chris J. Watson et al.

EUROPEAN JOURNAL OF HEART FAILURE (2015)

Article Pharmacology & Pharmacy

The potential role of valsartan+AHU377 (LCZ696) in the treatment of heart failure

Adriaan A. Voors et al.

EXPERT OPINION ON INVESTIGATIONAL DRUGS (2013)

Article Cardiac & Cardiovascular Systems

Effects of the novel angiotensin II receptor type I antagonist, fimasartan on myocardial ischemia/reperfusion injury

Jin Han et al.

INTERNATIONAL JOURNAL OF CARDIOLOGY (2013)

Review Peripheral Vascular Disease

Molecular biology of the natriuretic peptide system - Implications for physiology and hypertension

David G. Gardner et al.

HYPERTENSION (2007)

Article Cardiac & Cardiovascular Systems

Atrial natriuretic peptide helps prevent late remodeling after left ventricular aneurysm repair

H Tsuneyoshi et al.

CIRCULATION (2004)

Article Cardiac & Cardiovascular Systems

The effect of diabetes on outcomes of patients with advanced-heart failure in the BEST trial

M Domanski et al.

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2003)

Article Cardiac & Cardiovascular Systems

Prognostic impact of diabetes mellitus in patients with heart failure according to the etiology of left ventricular systolic dysfunction

DL Dries et al.

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2001)

Article Multidisciplinary Sciences

A genetic model provides evidence that the receptor for atrial natriuretic peptide (guanylyl cyclase-A) inhibits cardiac ventricular myocyte hypertrophy

I Kishimoto et al.

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2001)